Tamoxifen for relapse of ovarian cancer (Q24236581)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Tamoxifen for relapse of ovarian cancer (English)

0 references

0 references

1 reference

Chris Williams

1

0 references

Iveta Simera

series ordinal

2

0 references

Andrew Bryant

series ordinal

3

0 references

language of work or name

English

0 references

publication date

2010

0 references

published in

0 references

page(s)

CD001034

0 references

issue

3

0 references

cites work

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Measuring inconsistency in meta-analyses

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Meta-analysis in clinical trials

19 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

19 March 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Estrogen and progestin binding in cytosols of ovarian adenocarcinomas

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4235755

EUROCARE-3: survival of cancer patients diagnosed 1990-94--results and commentary.

30 May 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2F14651858.CD001034.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2F14651858.CD001034.PUB2

Tamoxifen therapy of epithelial ovarian cancer

21 January 2018

1 reference

12 December 2020

High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator

1 reference

12 December 2020

Experience with hormonal therapy in advanced epithelial ovarian cancer

1 reference

12 December 2020

A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer

1 reference

12 December 2020

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

1 reference

12 December 2020

Tamoxifen therapy in recurrent epithelial ovarian carcinoma

1 reference

12 December 2020

A phase II study of tamoxifen in ovarian cancer

1 reference

12 December 2020

Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma

1 reference

12 December 2020

Correlation between Steroid Hormone Receptors, Histological and Clinical Parameters in Ovarian Carcinoma

1 reference

12 December 2020

Tamoxifen in patients with advanced epithelial ovarian cancer

1 reference

12 December 2020

Cyclic hormonal treatment in ovarian cancer. A phase-II trial

1 reference

12 December 2020

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

12 December 2020

Estrogen receptor expression is a common feature of ovarian borderline tumors

1 reference

12 December 2020